Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and antiviral activity of IDX184 in
combination with pegylated interferon and ribavirin in treatment-naïve subjects with genotype
1 chronic hepatitis C virus (HCV) infection.